ReviewFrontiers in neuroscience2014
Advances in non-dopaminergic treatments for Parkinson's disease.
Review in Frontiers in neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Efficacy and safety of perampanel in Parkinson's disease. A systematic review with meta-analysis.Journal of neurology · 2018Pooled it
- Exosomes as Therapeutic and Diagnostic Tools: Advances, Challenges, and Future Directions.Cell biochemistry and biophysics · 2025Review
- Effects of puerarin on gait disturbance in a 6-hydroxydopamine mouse model of Parkinson's disease.Pharmacological reports : PR · 2025Article
- Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson's Disease.Current neuropharmacology · 2024Review
- Dopamine agonist monotherapy utilization in patients with Parkinson's disease.Clinical parkinsonism & related disorders · 2023Article
- Inhibition of PDE10A in a New Rat Model of Severe Dopamine Depletion Suggests New Approach to Non-Dopamine Parkinson's Disease Therapy.Biomolecules · 2022Article
- Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?Translational neurodegeneration · 2022Review
- Lippia grata essential oil complexed with β-cyclodextrin ameliorates biochemical and behavioral deficits in an animal model of progressive parkinsonism.Metabolic brain disease · 2022Article
- Phosphodiesterase 10A Inhibition Modulates the Corticostriatal Activity and L-DOPA-Induced Dyskinesia.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Olfactory Bulb DToxins · 2022Article
- The Evolving Landscape of Exosomes in Neurodegenerative Diseases: Exosomes Characteristics and a Promising Role in Early Diagnosis.International journal of molecular sciences · 2021Review
- Peripheral and Central Glutamate Dyshomeostasis in Neurodegenerative Disorders.Current neuropharmacology · 2021Article
- Research advances on L-DOPA-induced dyskinesia: from animal models to human disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Review
- Development of novelRSC advances · 2020Article
- Adipose-derived stem cells decreased microglia activation and protected dopaminergic loss in rat lipopolysaccharide model.Journal of cellular physiology · 2019Article
- Review
- Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice.Metabolic brain disease · 2018Article
- Role of adenosine AJournal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Unravelling the inhibitory activity of Chlamydomonas reinhardtii sulfated polysaccharides against α-Synuclein fibrillation.Scientific reports · 2018Article
- CIQ, a positive allosteric modulator of GluN2C/D-containing N-methyl-d-aspartate receptors, rescues striatal synaptic plasticity deficit in a mouse model of Parkinson's disease.CNS neuroscience & therapeutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the 1960's treatments for Parkinson's disease (PD) have traditionally been directed to restore or replace dopamine, with L-Dopa being the gold standard. However, chronic L-Dopa use is associated with debilitating dyskinesias, limiting its effectiveness. This has resulted in extensive efforts to develop new therapies that work in ways other than restoring or replacing dopamine. Here we describe newly emerging non-dopaminergic therapeutic strategies for PD, including drugs targeting adenosine, glutamate, adrenergic, and serotonin receptors, as well as GLP-1 agonists, calcium channel blockers, iron chelators, anti-inflammatories, neurotrophic factors, and gene therapies. We provide a detailed account of their success in animal models and their translation to human clinical trials. We then consider how advances in understanding the mechanisms of PD, genetics, the possibility that PD may consist of multiple disease states, understanding of the etiology of PD in non-dopaminergic regions as well as advances in clinical trial design will be essential for ongoing advances. We conclude that despite the challenges ahead, patients have much cause for optimism that novel therapeutics that offer better disease management and/or which slow disease progression are inevitable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.